Anrukinzumab

Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.[2]

Anrukinzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetIL13
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6452H9954N1714O2024S46
Molar mass145393.34 g·mol−1
 NY (what is this?)  (verify)

Anrukinzumab was developed by Wyeth.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.